Skip to content
The Vakona team.
The Vakona team.

Press release -

Multimillion SEK investment in Vakona signals start of production

Three investors are backing Umeå-based pharmaceutical company Vakona with funding worth millions of SEK.

“We are absolutely delighted and proud to have attracted this investment. It’s a reward for many years of hard work and takes us one step closer to clinical human trials”, says Gabriella Persson, CEO of Vakona.

Vakona is developing a new, antibiotic-free treatment for acne. The company has worked for several years with a natural bacterial protein identified by Oleg Alexeyev's research group at Umeå University that can be used as an effective treatment for acne, for example by application with skin cream.

“Acne vulgaris is the most common skin disease in the world, and affects more than 80 percent of all teenagers and young adults. Today's treatments still have many shortcomings, including long treatment times and poor results”, says Oleg Alexeyev, founder of Vakona.

Now three business angels and venture capital companies are backing Vakona with investments totaling SEK 15 million. The investors are Stoaf III SciTech, Phase2Phase Biopharma and Partnerinvest Norr.

“At last we can finally continue the development of our project and the production of our drug substance - and get one step closer to clinical trials on humans”, says Vakona's Chairman Mats Strömqvist. He adds:

“In addition to the capital itself, investors also contribute expertise in business development, networking and product development. This investment means a great deal to us”.

The global market for acne drugs is estimated to be worth almost $6 billion in 2021, and is expected to rise by 4–5.5 percent annually. It is a substantial market and Vakona hopes their product will become a market leader in the future.

“Right now there is a huge focus on beginning production of our drug candidate in accordance with the stringent requirements the regulatory authorities place on any new drug. We are also actively working to expand the company and continue to attract additional investors to help take us all the way to clinical trials. The goal is to start recruiting patients for our first clinical study in 2023, and to carry out the study in 2024”, says Gabriella Persson.

For further information, please contact:

Gabriella Persson, CEO, Vakona
gabriella.persson@ubicase.se
076-116 46 77

About Vakona

Vakona is developing a new, antibiotic-free treatment for inflammatory acne. The company works with a natural bacterial protein that breaks bacterial biofilm to open blocked hair follicles in acne. The protein can be used for effective treatment of acne, for example by application with skin cream. Vakona's treatment is currently in the preclinical phase.

www.vakona.se

Related links

Topics

Categories


Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Contacts

Tomas Ruuth

Tomas Ruuth

Press contact Head of PR & Communications PR & Communications 072-4024697 www.ubi.se

Related content

Jennie Ekbeck, CEO Umeå Biotech Incubator.

Umeå Biotech Incubator’s Jennie Ekbeck nominated for Sweden’s CEO of the Year

The CEO of Umeå Biotech Incubator (UBI), Jennie Ekbeck, has been named as one of five finalists in the small company category of Sweden’s CEO of the Year 2021.
“I was surprised and very happy to find out I had made it to the final. I feel really honoured”, says Jennie Ekbeck.
The award ceremony will be held at Fotografiska in Stockholm on 11th November.
A total of 20 nominees advanced to

Vakona.

New acne medicine takes one step closer to market launch

Umeå-based pharmaceutical company Vakona has signed an agreement with French company GTP Tech to initiate the first manufacturing steps of its acne medicine. “Production is at a level of quality that enables the medicine to be used in human clinical trials. If all goes well the medicine should be on the market within five to seven years”, says Mats Strömqvist, CEO and Chairman of the Board of Vak

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator
Umeå Biotech Incubator

Tvistevägen 48C
907 36 Umeå
Sweden